Trimer Capital

Ravi Viswanathan, the Founder and Managing Partner, leads the investment team and chairs the investment committee. He spent over a decade at NEA as a General Partner focused on growth-stage technology investments before leaving in 2019 to launch Trimer. Advisory Partner Mario Giannini provides institutional portfolio construction guidance, bringing his experience as the former CEO of Hamilton Lane. The investment committee is intentionally small, supporting a concentrated, high-conviction portfolio approach.

Trimer originates deal flow through a proprietary network of venture capital firms, corporate venture arms, founders, and early employees. The firm does not rely on traditional auction processes that dominate LP portfolio sales. Instead, it structures bilateral and limited-auction transactions, often when sellers need discrete, confidential liquidity before an IPO. The firm's model rewards relationships with the general partners whose portfolio companies are being traded.

Trimer is a registered investment adviser operating a private equity secondaries strategy. It does not invest in primary venture rounds, nor does it provide structured debt or preferred equity with credit-like protections. The firm buys existing, seasoned equity stakes from current shareholders, taking on the same class of shares those sellers held. Its fund structure — closed-end commingled vehicles — is typical of institutional private equity firms.

Trimer exclusively executes direct secondary transactions in single companies. It does not buy limited partnership interests in funds, does not invest in primary fund commitments, and does not pursue synthetic or derivatives-based exposure. The firm's entire strategy relies on underwriting individual, late-stage company outcomes directly.

The firm targets late-stage, venture-backed technology companies with at least $100 million in revenue and visible paths to a liquidity event within 12 to 36 months. It concentrates on enterprise software, fintech, and adjacent sectors where Viswanathan's NEA investment experience provides a diligence edge. The firm explicitly avoids deeply pre-revenue or clinical-stage biotech exposures, which carry binary risk profiles incompatible with its concentrated portfolio model.

Trimer does not sponsor continuation vehicles. It does not take an entire portfolio company off the hands of a GP, nor does it manage assets on an ongoing operating basis. Instead, it buys targeted, minority stakes from individual shareholders — often in companies where the lead venture investor remains actively involved. This provides sellers a clean exit, leaves the cap table dynamics intact, and avoids the governance complexity of GP-led restructurings.

Trimer operates as the sole or lead buyer in its transactions and does not actively syndicate co-investment alongside third-party GPs. The firm's origination and underwriting process is self-contained, and its fund documents grant wide discretion over position sizing. Trimer's principal-to-principal transaction model is designed to maximize control and confidentiality, which syndication would complicate.